Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Mineralys Therapeutics will report Q3 2026 financial results after market close on Wednesday, November 4, 2026, followed by a 4:30 p.m. ET conference call. The company's lead asset is lorundrostat, an investigational aldosterone synthase inhibitor targeting hypertension and related comorbidities.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.